Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2982772 in active plaque-type psoriasis
NCT02776033Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2016
- Primary completion
- Jan 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GSK2982772 in plaque psoriasis (4 arms), sponsored by GSK. Primary endpoints: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs, Number of Participants With Worst-case Post-Baseline Clinical Chemistry Results by Potential Clinical Importance (PCI) Criteria and 8 more. Started Aug 2016; status: completed.
02
Drugs
GSK2982772
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02776033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02776033.